News | November 13, 2024
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Q2 FY25 Total Income was at Rs. 85.4 crore
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Strokes are affecting approximately 1.8 million people annually
Subscribe To Our Newsletter & Stay Updated
